HealthEquity (NASDAQ:HQY) Director Sells $219,510.00 in Stock

HealthEquity, Inc. (NASDAQ:HQY) Director Gayle Furgurson Wellborn sold 2,439 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total transaction of $219,510.00. Following the transaction, the director directly owned 19,733 shares in the company, valued at approximately $1,775,970. The trade was a 11.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

HealthEquity Stock Up 3.0%

Shares of NASDAQ HQY traded up $2.65 during trading on Monday, reaching $90.64. 1,399,147 shares of the stock were exchanged, compared to its average volume of 1,017,490. The business’s 50-day moving average price is $83.44 and its 200 day moving average price is $86.67. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $116.65. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 33.95, a price-to-earnings-growth ratio of 1.60 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The business had revenue of $354.64 million for the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, equities analysts forecast that HealthEquity, Inc. will post 3.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Axiom Investment Management LLC bought a new stake in HealthEquity in the first quarter valued at $33,000. Summitry LLC increased its holdings in shares of HealthEquity by 10.3% in the 1st quarter. Summitry LLC now owns 4,371 shares of the company’s stock worth $365,000 after acquiring an additional 408 shares during the period. Bank of America Corp DE increased its holdings in shares of HealthEquity by 43.5% in the 1st quarter. Bank of America Corp DE now owns 862,008 shares of the company’s stock worth $72,038,000 after acquiring an additional 261,150 shares during the period. Janus Henderson Group PLC increased its holdings in shares of HealthEquity by 3.7% in the 1st quarter. Janus Henderson Group PLC now owns 850,411 shares of the company’s stock worth $71,068,000 after acquiring an additional 30,178 shares during the period. Finally, Amundi increased its holdings in shares of HealthEquity by 2,130.8% in the 1st quarter. Amundi now owns 67,592 shares of the company’s stock worth $5,649,000 after acquiring an additional 64,562 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Citizens Jmp upped their price target on shares of HealthEquity from $110.00 to $111.00 and gave the company a “market outperform” rating in a report on Monday. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a report on Tuesday, May 26th. Wall Street Zen cut shares of HealthEquity from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Deutsche Bank Aktiengesellschaft upped their price target on shares of HealthEquity from $120.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Finally, JPMorgan Chase & Co. cut their price target on shares of HealthEquity from $129.00 to $123.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $111.53.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.